BL22 immunotoxin (CAT-3888)
No longer in clinical development. Related to GCR-8015/CAT-8015, which have increased affinity to CD22.
Class/mechanism: Recombinant anti-CD22 immunotoxin fusion protein comprised of a murine anti-CD22 antibody fragment (disulphide-linked Fv, dsFv) and Pseudomonas exotoxin PE38. BL22 binds to CD22 positive cells and is endocytosed, resulting in intracellular release of the toxin and cell death.
- Abstract: R. J. Kreitman, W. H. Wilson, M. Stetler-Stevenson, P. Noel, I. Pastan. Long term follow-up of BL22 in cladribine-resistant hairy cell leukemia. 2004 ASCO Annual Meeting abstract 6624.
- Abstract: R. J. Kreitman, W. H. Wilson, M. Stetler-Stevenson, P. Noel, D. J. FitzGerald, I. Pastan. Phase II trial of CAT-3888 (BL22) in chemo-resistant hairy cell leukemia. 2007 ASCO Annual Meeting abstract 7095.
- Kreitman RJ, Stetler-Stevenson M, Margulies I, Noel P, Fitzgerald DJ, Wilson WH, Pastan I. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol. 2009 Jun 20;27(18):2983-90. Epub 2009 May 4. link to original article PubMed
Also known as
- Code name: GCR-3888